Opna Bio

Opna Bio is a private, clinical-stage oncology biotech founded in 2021, leveraging a deep scientific foundation in the Hallmarks of Cancer. The company's strategy centers on designing small molecule inhibitors and degraders with differentiated pharmacokinetic profiles, such as 'pulsatile dosing,' to improve safety and efficacy. Its most advanced assets, the BET inhibitor zavabresib (OPN-2853) and the EP300 inhibitor OPN-6602, are in early-stage clinical trials for myelofibrosis and multiple myeloma, respectively. The leadership team, including co-founder and CSO Gideon Bollag, has a proven track record of advancing multiple drugs to FDA approval.

Rational design of epigenetic modulators and protein degraders with unique pharmacokinetic profiles (e.g., 'pulsatile dosing'), and research into novel cancer targets like FMRP.

In myelofibrosis, zavabresib competes with other BET inhibitors in development and must differentiate itself from JAK inhibitors and novel combo regimens. In multiple myeloma, OPN-6602 enters a crowded field and must prove superiority or complementary activity to established therapies. The protein degrader space is highly competitive, with several well-funded biotechs and pharma companies pursuing similar platforms.